Deacon CF, Nauck MA, ToftNielsen M, Pridal L, Willms B, Holst JJ
The Glycopyrrolate Effect on syMptoms and lung function studies (GEM1 and GEM2) evaluated the efficacy and safety of glycopyrrolate 15.6mcg administered BID via DPI in patients with moderate to severe COPD
In blood, however, the markers of neuronal damage moved the wrong way: neurofilament light, a marker of axonal injury, rose by about 5 percent in one of the two trials, and glial fibrillary acidic protein, a marker of astroglial activation, rose by about 4 percent in both
Biol Neonate 1990;58:89-92
doi: 10.1007/s13205-013-0117-5
These preliminary findings remain of uncertain clinical relevance and do not suggest altered infection susceptibility